PPH or RSPH or XLV

Key Takeaways

• PPH offers concentrated exposure to 25-26 global pharmaceutical leaders via market-cap weighting, resulting in top-heavy holdings (top 10 ~70-73%) but pure pharma focus.
• RSPH provides broad U.S. health care diversification across ~59 S&P 500 names with equal weighting (~1.7% each), reducing mega-cap dominance and enhancing mid-tier exposure.
• XLV delivers market-cap weighted access to ~60 large-cap U.S. health care firms, balancing pharma (~36%) with providers, biotech, and equipment at the lowest expense ratio (0.08%).
• Cost efficiency favors XLV (0.08%), followed by PPH (0.36%) and RSPH (0.40%), impacting long-term net returns.
• PPH exhibits higher concentration risk but global pharma tilt; RSPH offers superior diversification; XLV provides high liquidity and scale with $37B+ AUM (assets under management, total value of fund assets).
• In recent months, pharma-focused PPH showed relative resilience amid sector volatility, while equal-weight RSPH mitigated drawdowns better than cap-weighted peers.

Introduction

PPH, RSPH, and XLV represent distinct strategic approaches within the health care sector, a defensive powerhouse amid economic uncertainty. PPH targets pharmaceuticals exclusively through a global, cap-weighted index of top firms. RSPH applies equal-weighting to S&P 500 health care stocks for balanced exposure across sub-industries. XLV tracks the cap-weighted Health Care Select Sector Index from the S&P 500, emphasizing large-cap leaders. These ETFs compete in a sector driven by innovation in biotech and drugs, yet diverge in geographic scope (PPH global vs. others U.S.-focused), weighting (cap vs. equal), and breadth (narrow pharma vs. full health care). Comparing them aids investors navigating regulatory pressures, aging demographics, and AI-driven drug discovery trends.

VanEck Pharmaceutical ETF (PPH) Overview

The VanEck Pharmaceutical ETF (PPH) tracks the MVIS US Listed Pharmaceutical 25 Index, focusing on the largest and most liquid U.S.-listed pharmaceutical companies involved in research, development, production, marketing, and sales of drugs. It holds 25-26 stocks in a market-cap weighted, non-diversified structure, with top 10 holdings comprising ~70-73% of assets. Key positions include LLY (~18-20%), NVS (~10-11%), MRK (~9%), NVO (~5-6%), and PFE (~5%). Sector allocation is nearly 100% health care, primarily pharmaceuticals, with ~60% U.S. and 40% international exposure. The expense ratio is 0.36%. As a passive, concentrated fund, PPH rebalances quarterly to maintain liquidity and market-cap alignment, offering targeted access to pharma innovation leaders.

Invesco S&P 500 Equal Weight Health Care ETF (RSPH) Overview

The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) replicates the S&P 500 Equal Weight Health Care Index, equally allocating (~1.7%) across all health care constituents of the S&P 500. It features ~59 holdings, promoting diversification beyond mega-caps. Top 10 (~21-22%) include CNC (~2.6%), HUM (~2.5%), UNH (~2.3%), ELV (~2.3%), and WST (~2.2%), spanning providers, pharma, and devices. Sector breakdown: ~68% health technology, ~22% health services, ~6% distribution. Expense ratio: 0.40%. This smart beta, passive ETF rebalances quarterly to reset equal weights, reducing concentration risk while capturing S&P 500 health care breadth.

Health Care Select Sector SPDR Fund (XLV) Overview

The Health Care Select Sector SPDR Fund (XLV) follows the Health Care Select Sector Index, comprising large-cap S&P 500 health care firms. It holds ~60 stocks market-cap weighted. Top 10 (~59%) feature LLY (~14%), JNJ (~10%), ABBV (~7%), UNH (~6-7%), and MRK (~5%). Sub-sector allocation: pharmaceuticals (36%), providers & services (19%), biotech (18%), equipment & supplies (17%), life sciences tools (9%). Expense ratio: 0.08%. As a passive benchmark tracker with massive scale ($37B AUM), XLV rebalances with S&P adjustments (typically quarterly), delivering liquid, broad U.S. health care exposure.

Industry and Thematic Landscape

The health care sector, encompassing these ETFs, benefits from structural tailwinds like aging populations boosting demand for drugs and services, alongside AI accelerating drug discovery and personalized medicine. Macro drivers include resilient earnings from essential services amid economic cycles, though inflation in labor and supplies pressures margins. Recent capital flows into health care ETFs surged in late 2025 ($6.8B in November), signaling optimism post-policy resets. Regulatory shifts, such as resolved U.S. drug pricing uncertainties and potential ACA subsidy changes, introduce volatility, while geopolitical tensions elevate supply chain risks for pharma. Geopolitical influences like trade dynamics affect global firms in PPH. Sector risks include policy reforms (e.g., Medicare changes) and litigation, balanced by innovation in GLP-1 drugs and biotech M&A (mergers and acquisitions, company buyouts).

Performance and Positioning Comparison

In recent weeks and months through early 2026, health care ETFs faced headwinds from policy fears and rising rates, posting YTD declines: PPH ~-2.4%, RSPH ~-3.8%, XLV ~-6.9%. Over trailing 12 months, PPH led with ~20% gains, driven by pharma heavyweights like LLY, followed by RSPH and XLV at ~9%. Relative volatility shows PPH highest (~18% 1Y), XLV lowest (~15%), with RSPH in between, owing to equal-weighting dampening mega-cap swings. Drawdowns in recent cycles were shallower for RSPH due to diversification, while PPH's concentration amplified gains in pharma rallies but heightened sensitivity to drug setbacks. XLV's scale ensures trend consistency and low tracking error. Differences stem from weighting—equal (RSPH) vs. cap (others)—and scope: PPH's pharma purity outperforms in drug booms, XLV balances providers' stability.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (total value of outstanding shares), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes like health care ETFs.

Tickeron AI Verdict

Tickeron’s AI favors XLV with ~60% probability in the current environment due to superior cost efficiency (0.08% expense ratio), massive liquidity, balanced diversification across health sub-sectors, and stable momentum in recent market cycles. PPH (~25%) suits pure pharma bets, while RSPH (~15%) appeals for equal-weight risk reduction. Selection emphasizes structural advantages over short-term trends, without constituting advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations